Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma | Zendy

Yaojun Zhang | Zendy; Mengping Zhang | Zendy; Minshan Chen | Zendy; Jie Mei | Zendy; Li Xu | Zendy; Rong Guo | Zendy; Xiaojun Lin | Zendy; Jiaping Li | Zendy; Zhenwei Peng | Zendy

Open Access

Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma

Author(s) -

Yaojun Zhang,

Mengping Zhang,

Minshan Chen,

Jie Mei,

Li Xu,

Rong Guo,

Xiaojun Lin,

Jiaping Li,

Zhenwei Peng

Publication year - 2018

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2018.3213

Subject(s) - medicine , cohort , hepatocellular carcinoma , progressive disease , response evaluation criteria in solid tumors , complete response , gastroenterology , radiological weapon , disease , oncology , surgery , chemotherapy

Key Points Question Is there an early reliable surrogate end point for overall survival (OS) in patients with hepatocellular carcinoma after conventional transarterial chemoembolization? Findings In this cohort study of 2734 patients in China, sustained response duration of 6 months or more was found to have the strongest association with 5-year OS after chemoembolization. Sustained response duration of 6 months or more was found to be the independent prognostic factor for OS. Meaning Sustained response duration of 6 months or more was associated with OS and may serve as an early surrogate end point after conventional transarterial chemoembolization for intermediate hepatocellular carcinoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research